Henlius’ HLX04-O (biosimilar, bevacizumab) Receives the US FDA’s IND Approval for wAMD

Shots:

• The US FDA has approved the IND application of HLX04-O for the treatment of wAMD
• The P-III clinical study of HLX04-O will be conducted to further evaluate the efficacy and safety of HLX04-O in patients with wAMD in the near future. The study will enroll 388 patients from Chinese mainand, Australia, Russian Federation, Singapore, Spain and Poland
• Henlius and Essex will speed up the global clinical trials of HLX04-O and apply approval in different countries and regions across the globe based on the research results

Click here to­ read full press release/ article | Ref: Henlius | Image: Henlius